Project Grant R61CA315147
Award Date 8/1/26
Completion Date 7/31/29
Dollars Obligated $225K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
- The National Cancer Institute awarded The University of Chicago $388,234 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop sequencing technology for studying small nucleolar RNA (snoRNA) targets and their roles in cancer. The research encompasses two primary aims. Aim 1 will enhance the sensitivity and resolution of snoRNA-enriched kethoxal-assisted RNA-RNA sequencing (SNOKARR-SEQ) to identify low-abundance snoRNA targets in cancer cells using mutation...
- The National Cancer Institute awarded the University of Illinois $824,498 on May 13, 2026, under the Cancer Biology Research program (CFDA 93.396) to identify novel innate immune checkpoint receptors that regulate phagocytosis and govern cancer immune evasion. The funded research focuses on the VCAM1-receptor axis as a therapeutic target for leukemia and allogeneic transplantation. Specific Aim 1 will identify the VCAM1 receptor on phagocytic cells that promotes immune tolerance and leukemia...
- The National Cancer Institute awarded the University of Illinois $665,257 on September 3, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop molecular diagnostic methods for cervical cancer screening. The recipient will develop and validate a loop-mediated isothermal amplification (LAMP)-based assay for detecting high-risk human papillomavirus (HPV) infection in cervical samples, designed for point-of-care deployment in low-resource settings where access...
- The National Cancer Institute awarded The University of Chicago $588,289 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to characterize how BH3-mimetic drugs alter T cell function through BCL-2 family protein-protein interactions, with the goal of informing T cell-based cancer therapies. The project investigates the non-apoptotic immunomodulatory effects of BH3-mimetic compounds on human T cells used in adoptive cell therapy. While BH3 mimetics are known to induce...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded the Regents of the University of Michigan $669,278 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop microbial-based cancer therapeutics engineered to deliver localized immune activation while minimizing systemic toxicity. The research focuses on nonpathogenic, tumor-tropic E. coli engineered to display membrane-anchored cytokines, specifically decoy-resistant...
- The National Cancer Institute awarded The Broad Institute, Inc. $694,642 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop live-cell RNA sequencing with single-cell resolution. The project addresses a fundamental limitation in molecular omics measurement: current approaches require cell destruction through lysis, extraction, or fixation to detect molecular contents at high multiplexity, preventing serial measurement of living cells to monitor dynamic processes...
- Federal Project Grant Award Summary The University of Chicago received a $372,628 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) effective September 12, 2025, with completion targeted for August 31, 2028. This award supports research into spatiomolecular profiling of human cancer at scale, specifically focused on developing and advancing spatially resolved transcriptomics (ST) technologies for analyzing tumor...
- The National Cancer Institute awarded The University of Chicago $518,151 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate nicotinamide N-methyltransferase (NNMT) inhibition as a strategy to sensitize ovarian and colorectal cancers to immune checkpoint inhibitors. The award funds research targeting NNMT expression in cancer-associated fibroblasts within the tumor microenvironment. The project will investigate whether NNMTI'960, a small-molecule NNMT...
- The National Cancer Institute awarded the University of Illinois $3.38 million on April 1, 2026, under the Cancer Centers Support Grants program (CFDA 93.397) to support the Cancer Center at Illinois (CCIL), a research center that integrates engineering and basic sciences to transform cancer research, detection, and treatment. The CCIL operates under a discovery-to-use paradigm with two core research programs—Cancer Technology & Data Science and Cancer Engineering & Biological...
- The National Cancer Institute awarded The Jackson Laboratory $452,458 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to advance and validate single-cell long-read sequencing for cancer molecular profiling. The project develops and validates enhanced tools for single-cell long-read isoform transcriptomics (SCLR-SEQ) to map and analyze full-length spliced isoforms at single-cell resolution in tumor samples. The work addresses technical gaps in current approaches,...